WallStreetZenWallStreetZen

NASDAQ: IOVA
Iovance Biotherapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Iovance Biotherapeutics revenue was $212.68M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $49.3M, down 33.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IOVA annual revenue was $164.1M, with 13,699% growth year-over-year.

IOVA past revenue growth

How has IOVA's revenue growth performed historically?

Company
11,070.12%
Industry
1,487.15%
Market
35.58%
IOVA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IOVA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IOVA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IOVA revenue history

Current Revenue
$212.7M
Current Earnings
-$375.4M
Current Profit Margin
-176.5%

Be the first to know when IOVA announces revenue.

IOVA Revenue History By Year

IOVA Yearly RevenueIOVA RevenueIOVA ChangeIOVA Revenue Growth
2024-12-31$164.07M$162.88M+13,698.99%
2023-12-31$1.19MN/AN/A
2022-12-31$0.00N/AN/A
2021-12-31$0.00N/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A
2010-12-31$0.00N/AN/A
2009-12-31$0.00N/AN/A
2008-12-31$0.00N/AN/A
2007-12-31$0.00N/AN/A

1 of 2

Iovance Biotherapeutics Revenue FAQ

What was IOVA's revenue last quarter?

On Invalid Date, Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 2025 revenue of $49.32 million up 6,798.46% year over year. In the same quarter last year, Iovance Biotherapeutics's revenue was $715.00 thousand.

What was Iovance Biotherapeutics's revenue in 2024?

Iovance Biotherapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $164.07 million, a 13,698.99% increase year over year.

How much does Iovance Biotherapeutics make in a day?

Based on Iovance Biotherapeutics annual revenue for the past five years, IOVA makes an average of $90,552.88 per day.

What was Iovance Biotherapeutics's annual revenue growth in the past year?

As of Q3 2025, Iovance Biotherapeutics's revenue has grown 11,070.12% year over year. This is 9,582.96 percentage points higher than the US Biotechnology industry revenue growth rate of 1,487.15%. Iovance Biotherapeutics's revenue in the past year totaled $212.68 million.

How much does Iovance Biotherapeutics make in a year?

Iovance Biotherapeutics's revenue by year for the past five years is:
  • Iovance Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $164.07 million, a 13,698.99% increase year over year.
  • Iovance Biotherapeutics's annual revenue for Dec 31, 2023 was $1.19 million, a Infinity% increase from 2022.
  • Iovance Biotherapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
  • Iovance Biotherapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
  • Iovance Biotherapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.